Pulmonary Hypertension Prevention in Hemodialysis

New Phosphore Binders in Prevention of Pulmonary Hypertension

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01350687

Enrollment

Registered

2011-05-10

Start date

2011-06-30

Completion date

2014-06-30

Last updated

2011-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease

Keywords

Calcium Phosphore, Renagel

Brief summary

Pulmonary hypertension is a new complication described in hemodialysis patients. in the last year these patients were treated by calcium carbonate orally to control serum phosphor. Calcium phosphor deposits in pulmonary artery can explain this phenomena. The investigators want to investigate the new phosphor non calcium containing agents in hemodialysis patients and to measure the pulmonary pressure.

Detailed description

The investigators will measure pulmonary blood pressure before and after treatment with new phosphor binders, non calcium containing.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Hemodialysis Patients without fistula

Exclusion criteria

* Heart Disease

Countries

Israel

Outcome results